Hosted on MSN11mon
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, PelabresibIn the deal press release, MorphoSys CEO Jean-Paul Kress said, “Pelabresib — the investigational therapy at the forefront of our promising oncology pipeline — has the potential to shift the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback